Further research is necessary to elucidate the precise mechanisms by which GPR30 and the PI3K/Akt pathway interact to modulate the effects of an HFD and to determine how these pathways can be targeted for therapeutic interventions in metabolic disorders. This evidence concerns the gene AKT1 and metabolic disease.